Cargando…

Targeting mutant p53 for cancer therapy

Detalles Bibliográficos
Autores principales: Oren, Moshe, Tal, Perry, Rotter, Varda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931821/
https://www.ncbi.nlm.nih.gov/pubmed/27347904
http://dx.doi.org/10.18632/aging.100992
_version_ 1782440965381816320
author Oren, Moshe
Tal, Perry
Rotter, Varda
author_facet Oren, Moshe
Tal, Perry
Rotter, Varda
author_sort Oren, Moshe
collection PubMed
description
format Online
Article
Text
id pubmed-4931821
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-49318212016-07-18 Targeting mutant p53 for cancer therapy Oren, Moshe Tal, Perry Rotter, Varda Aging (Albany NY) Editorial Impact Journals LLC 2016-06-26 /pmc/articles/PMC4931821/ /pubmed/27347904 http://dx.doi.org/10.18632/aging.100992 Text en Copyright: © 2016 Oren et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Oren, Moshe
Tal, Perry
Rotter, Varda
Targeting mutant p53 for cancer therapy
title Targeting mutant p53 for cancer therapy
title_full Targeting mutant p53 for cancer therapy
title_fullStr Targeting mutant p53 for cancer therapy
title_full_unstemmed Targeting mutant p53 for cancer therapy
title_short Targeting mutant p53 for cancer therapy
title_sort targeting mutant p53 for cancer therapy
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931821/
https://www.ncbi.nlm.nih.gov/pubmed/27347904
http://dx.doi.org/10.18632/aging.100992
work_keys_str_mv AT orenmoshe targetingmutantp53forcancertherapy
AT talperry targetingmutantp53forcancertherapy
AT rottervarda targetingmutantp53forcancertherapy